Detail akcie Tango Therapetcs Rg online

Business Summary: Tango Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to discovering novel drug targets and delivering precision medicine for the treatment of cancer. The Company's novel small molecules are designed to be selectively active in cancer cells with specific genetic alterations, killing those cancer cells while sparing normal cells. It is also extending its target space beyond the classic, cell-autonomous effects of tumor suppressor gene loss. It is engaged in developing two methylthioadenosine (MTA)-cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors: TNG462 for non- central nervous system (CNS) cancers, including pancreatic and lung cancer, and TNG456, brain-penetrant PRMT5 inhibitor, for CNS cancers, including glioblastoma (GBM). Its TNG260 is a first-in-class Co-repressor of Repressor Element-1 Silencing Transcription (CoREST) inhibitor, which in preclinical studies reversed the immune evasion effect of STK11 loss-of-function mutations.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Tango Therapeutics Inc revenues increased 64% to $62.4M. Net loss decreased 32% to $62.8M. Revenues reflect Collaboration revenue increase from $25.9M to $62.4M. Lower net loss reflects Research and development - Balancing val decrease of 10% to $88.3M (expense), Stock-based Compensation in SGA decrease of 10% to $8.7M (expense).